Mostrar el registro sencillo del ítem
dc.contributor.author | Serrano-Villar, Sergio | |
dc.contributor.author | Lopez-Huertas, Maria Rosa | |
dc.contributor.author | Jiménez, Daniel | |
dc.contributor.author | Galera, Carlos | |
dc.contributor.author | Martínez-Sanz, Javier | |
dc.contributor.author | Moreno, Elena | |
dc.contributor.author | Muriel, Alfonso | |
dc.contributor.author | Gutiérrez, Félix | |
dc.contributor.author | Busca, Carmen | |
dc.contributor.author | Portilla, Joaquín | |
dc.contributor.author | Bisbal, Otilia | |
dc.contributor.author | Iribarren, José Antonio | |
dc.contributor.author | Tejerina, Francisco | |
dc.contributor.author | de los Santos, Ignacio | |
dc.contributor.author | Moreno, Santiago | |
dc.contributor.author | CoRIS Cohort | |
dc.date.accessioned | 2022-05-24T11:00:15Z | |
dc.date.available | 2022-05-24T11:00:15Z | |
dc.date.issued | 2022-03-14 | |
dc.identifier.citation | Front Immunol. 2022 Mar 14;13:848630. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/14485 | |
dc.description.abstract | Background: Because inflammation is associated with mortality and has been linked to HIV transcription in lymphoid tissues during ART, it is necessary to address the long-term effects of switching 3-drug (3DR) to 2-drug regimens (2DR) on inflammation. Methods: Nested study in the Spanish AIDS Research Network. We selected PWH ART-naive initiating 3DR who achieved viral suppression in the first 48 weeks and either remained on 3DR or switched to 2DR (3TC+bPI; 3TC+DTG; DTG+RPV). We assessed the trajectories on inflammatory markers during ART using multivariate piecewise mixed models. Results: We analyzed 619 plasma samples from 148 patients (3DR, N=90; 2DR, N=58), the median follow-up was 4.6 (IQR 3.2-6.2) years. There were no significant differences in baseline characteristics between groups. After adjusting for potential confounders, patients with 3DR experienced a slow decline of IL6, hs-CRP, sCD14, sCD163, and D-dimer over time. In contrast, compared to 3DR, switching to 2DR was associated with increases in IL-6 (p=0.001), hs-CRP (p=0.003), and D-dimer (p=0.001) after year 3 from virologic suppression. 2DR was associated with a higher risk of hs-CRP quartile increase (aOR 3.3, 95%CI 1.1-10) and D-dimer quartile increase (aOR 3.7, 95%CI 1.1-13). The adjusted biomarker trajectories did not reveal a distinct pattern according to the type of 2DR used (bPI vs DTG). Conclusions: In this study in virally suppressed individuals, maintaining 3DR was associated with a more favorable long-term inflammatory profile than switching to 2DR. The potential clinical implications of these findings on the development of non-AIDS events deserve further investigation. | es_ES |
dc.description.sponsorship | The HIV BioBank, integrated in the Spanish AIDS Research Network, is supported by Instituto de Salud Carlos III, Spanish Health Ministry (Grant n° proyectos RD06/0006/0035, RD12/0017/0037 and RD16/0025/0019) as part of the Plan Nacional R + D + I and co-financed by the European Development Regional Fund ‘‘A way to achieve Europe’’ (ERDF). The RIS Cohort (CoRIS) is funded by the Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en SIDA (RIS C03/173, RD12/0017/0018 and RD16/0002/0006) as part of the Plan Nacional R+D+I and cofinanced by ISCIII-Subdirección General de Evaluacion and Fondo Europeo de Desarrollo Regional (FEDER)”. This work was supported by the Instituto de Salud Carlos III projects AC17/00019, PI18/00154, ICI20/00058, CIBER de Enfermedades Infecciosas, and Gilead Sciences (Investigator Sponsored Research ISR-17-10192). The funders had no role in the study design, data analysis, or in the interpretation of the results. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | HIV | es_ES |
dc.subject | Antiretroviral therapy | es_ES |
dc.subject | C reactive protein | es_ES |
dc.subject | D-dimer | es_ES |
dc.subject | Inflammation | es_ES |
dc.title | Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 35359950 | es_ES |
dc.format.volume | 13 | es_ES |
dc.format.page | 848630 | es_ES |
dc.identifier.doi | 10.3389/fimmu.2022.848630 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Ministerio de Sanidad (España) | es_ES |
dc.contributor.funder | Plan de Recuperación, Transformación y Resiliencia (España) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Red de Investigación Cooperativa en Investigación en Sida (España) | es_ES |
dc.contributor.funder | Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas) | es_ES |
dc.contributor.funder | Gilead Sciences (Spain) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1664-3224 | es_ES |
dc.relation.publisherversion | https://doi.org/10.3389/fimmu.2022.848630 | es_ES |
dc.identifier.journal | Frontiers in Immunology | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD06/0006/0035 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD12/0017/0037 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD16/0025/0019 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RISC03/173 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD12/0017/0018 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD16/0002/0006 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/AC17/00019 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI18/00154 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/ICI20/00058 | es_ES |